Cardio3 BioSciences becomes Celyad
16 April 2015 | By Victoria White
Cardio3 BioSciences, a leader in engineered cell therapies, has announced its intention to change its corporate name to 'Celyad'...
List view / Grid view
News
Isarna initiates first-in-human Phase I trial for ISTH0036 to treat advanced glaucoma
16 April 2015 | By Victoria White
Isarna has initiated the Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-ß2 to treat advanced glaucoma...
Effimune obtains regulatory approval for Phase I clinical trial of FR104
16 April 2015 | By Victoria White
The FAMHP has given authorisation for the commencement of the Phase I clinical trial of FR104, a drug for controlling the regulation of the immune system...
InVivo Therapeutics announces uplisting to Nasdaq
16 April 2015 | By Victoria White
InVivo Therapeutics Holdings Corp. (NVIV) has announced that its common stock has been approved to begin trading on The Nasdaq Capital Market...
Phase II data for apremilast in Behçet’s disease published
16 April 2015 | By Victoria White
Results from a multicentre, randomized, placebo-controlled phase II trial (BCT-001) of apremilast in patients with Behçet's disease have been published...
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod
16 April 2015 | By Victoria White
Active Biotech and Ipsen discontinue the development of prostate cancer drug tasquinimod and have released top line results for the 10TASQ10 study...
Actelion initiates Phase III development of ponesimod for patients with relapsing MS
16 April 2015 | By Victoria White
Actelion has initiated Phase III development with ponesimod, its lead compound, in patients suffering from relapsing multiple sclerosis (MS)...
Melanoma treatment market value to more than quadruple to $5.64 billion by 2023, reports GlobalData
16 April 2015 | By Victoria White
The melanoma treatment market will increase from $1.34 billion in 2013 to $5.64 billion by 2023, representing a robust CAGR of 15.5%, reports GlobalData...
Positive clinical study results reported for évolis ONE – a hair growth product using novel FGF5 inhibitor
16 April 2015 | By Victoria White
Cellmid Limited has reported strong positive results in its independently conducted, blinded and placebo controlled human clinical study of évolis ONE...
Pivotal Phase 3 clinical trial of SGX203 in paediatric Crohn’s Disease given green light
15 April 2015 | By Victoria White
Soligenix and the FDA have reached an agreement on the design of a pivotal Phase 3 trial evaluating SGX203 in the treatment of paediatric Crohn’s disease...
Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden
15 April 2015 | By Victoria White
The Phase 2 clinical trial of Imprime PGG and bevacizumab achieved meaningful reductions in tumour burden in patients with non-small cell lung cancer...
The global treatment market for Duchenne Muscular Dystrophy will expand to $990 million by 2019, says GlobalData
15 April 2015 | By Victoria White
The global treatment market for Duchenne Muscular Dystrophy will expand in value at a CAGR of 160.5% to $990 million by 2019, says GlobalData...
Pfizer announces IBRANCE Phase 3 PALOMA-3 trial met primary endpoint
15 April 2015 | By Victoria White
The Phase 3 PALOMA-3 trial for IBRANCE has been stopped early due to efficacy seen in women with HR+, HER2- metastatic breast cancer...
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
WHO calls for the disclosure of results from all clinical trials for medical products
15 April 2015 | By Victoria White
WHO has issued a public statement calling for the disclosure of results from clinical trials for medical products, whatever the result...
